戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  based on factors associated with the use of postoperative chemotherapy.
2 eoadjuvant chemoradiotherapy do not complete postoperative chemotherapy.
3 node involvement (pN) of primary cancer, and postoperative chemotherapy.
4 val of 90% (77-100) and did not benefit from postoperative chemotherapy.
5 ar invasion, perineural invasion, and use of postoperative chemotherapy.
6 ic factor and is used to guide the choice of postoperative chemotherapy.
7 motherapy followed by definitive surgery and postoperative chemotherapy.
8 d chemotherapy and 27 received both pre- and postoperative chemotherapy.
9  received induction chemotherapy, as well as postoperative chemotherapy.
10 ols treated with chemoradiotherapy, TME, and postoperative chemotherapy.
11                         Do all patients need postoperative chemotherapy?
12  excised compared with patients who received postoperative chemotherapy (113 cm vs. 213 cm, P = 0.004
13  a further nine cycles of OxMdG) or standard postoperative chemotherapy (12 cycles of OxMdG).
14             After completing three cycles of postoperative chemotherapy, 216 eligible patients were r
15 extrahepatic disease (P=0.34) or type of pre/postoperative chemotherapy (5-FU-leucovorin vs. FOLFOX/F
16               We sought to determine whether postoperative chemotherapy after preoperative therapy an
17 ly to patients with poor prognostic factors, postoperative chemotherapy after preoperative therapy an
18 event-free survival compared with the use of postoperative chemotherapy alone.
19 y; surgery on day 57; and one more course of postoperative chemotherapy and 12 to 18 Gy of concurrent
20 hort comprised 122 patients: 61 who received postoperative chemotherapy and 61 who did not.
21 ment and pancreatectomy, 155 (63%) initiated postoperative chemotherapy and 90 (37%) did not.
22 examine the efficacy and safety of intensive postoperative chemotherapy and focal radiation to treat
23                                              Postoperative chemotherapy and radiation therapy improve
24                 Pancreaticoduodenectomy with postoperative chemotherapy and radiation therapy is asso
25 tient was treated by surgical resection with postoperative chemotherapy and radiation.
26 th resected head and neck cancer, concurrent postoperative chemotherapy and radiotherapy significantl
27         Intended treatment included pre- and postoperative chemotherapy and surgery.
28   Prospective evaluation of whether omitting postoperative chemotherapy and/or switching to a noncros
29 d 1.92); CEA more than 200 ng/mL, absence of postoperative chemotherapy, and extrahepatic disease wer
30  of RER status could affect initial therapy, postoperative chemotherapy, and follow-up.
31 l samples, serial samples during any pre- or postoperative chemotherapy, and serial samples in follow
32 mab, generally administered for 1 year after postoperative chemotherapy, are appropriate consideratio
33 ry by 12 weeks from diagnosis, and modifying postoperative chemotherapy based on histologic response.
34 der patients with SCA, a randomized trial of postoperative chemotherapy compared with observation alo
35 58-3.72) disease were more likely to receive postoperative chemotherapy compared with older patients.
36                                              Postoperative chemotherapy did not alter outcomes.
37 aturely after compelling evidence supporting postoperative chemotherapy emerged.
38 ative risk factors for survival and pre- and postoperative chemotherapy exposure were analyzed.
39              Patients received two cycles of postoperative chemotherapy followed by 45 Gy of radiatio
40  testing the feasibility and safety of early postoperative chemotherapy followed by concurrent chemor
41 (NAC) has potential advantages over standard postoperative chemotherapy for locally advanced colon ca
42 S-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour sho
43 and debate surrounding the issue of pre- and postoperative chemotherapy for patients with localized s
44              Previous studies suggested that postoperative chemotherapy had not improved the prognosi
45 ant brain tumors were treated with prolonged postoperative chemotherapy in an effort to delay irradia
46     At present, stronger evidence exists for postoperative chemotherapy in early-stage NSCLC.
47 ents after reports of a survival benefit for postoperative chemotherapy in other studies.
48  the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly respo
49 s no consensus about the survival benefit of postoperative chemotherapy in stage II colon cancer.
50                       The addition of CRT to postoperative chemotherapy in young children with nonmet
51                 For more than three decades, postoperative chemotherapy-initially fluoropyrimidines a
52 of adding secondary cytoreductive surgery to postoperative chemotherapy on progression-free survival
53 anced setting, perioperative chemotherapy or postoperative chemotherapy or chemoradiation improves ou
54 despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical p
55                  No patient received pre- or postoperative chemotherapy or radiation therapy.
56                            98% (50 of 51) of postoperative chemotherapy patients had T3 or more advan
57 n rate, the survival benefit associated with postoperative chemotherapy (PC) is unclear in patients w
58 Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, i
59                                     However, postoperative chemotherapy plus chemoradiotherapy, in th
60      Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilm
61 ents who will suffer recurrence and for whom postoperative chemotherapy significantly prolonged survi
62               For those patients who require postoperative chemotherapy, standard therapy consists of
63 apy treatments have included the addition of postoperative chemotherapy, the addition of brachytherap
64  outcome of poor responders by modifying the postoperative chemotherapy, their prognosis remains poor
65               Of those receiving any pre- or postoperative chemotherapy, three patients received chem
66 tients were treated with the intent of using postoperative chemotherapy to delay planned irradiation.
67  lung cancer resection and the initiation of postoperative chemotherapy to determine the association
68                Data to support administering postoperative chemotherapy to patients who received preo
69 nse to neoadjuvant chemotherapy to determine postoperative chemotherapy; to evaluate a uniform histol
70 ates similar to those observed in randomized postoperative chemotherapy trials.
71                             Preoperative and postoperative chemotherapy was defined as chemotherapy g
72           Patients in CR received three-drug postoperative chemotherapy, whereas patients not in CR w
73 erapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well
74 dition of secondary cytoreductive surgery to postoperative chemotherapy with paclitaxel plus cisplati
75                                      Minimal postoperative chemotherapy with two cycles of cisplatin,
76 rioperative (12 weeks preoperative, 12 weeks postoperative) chemotherapy with either fluorouracil, ir